Pituitary-independent effect of octreotide on IGF1 generation

Ana Pokrajac, Jan Frystyk, Allan Flyvbjerg, Peter J. Trainer

    Research output: Contribution to journalArticlepeer-review


    Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH
    Original languageEnglish
    Pages (from-to)543-548
    Number of pages5
    JournalEuropean Journal of Endocrinology
    Issue number4
    Publication statusPublished - 2009


    Dive into the research topics of 'Pituitary-independent effect of octreotide on IGF1 generation'. Together they form a unique fingerprint.

    Cite this